Cooper Financial Group Increases Stake in Zoetis Inc. (NYSE:ZTS)

Cooper Financial Group raised its holdings in shares of Zoetis Inc. (NYSE:ZTSGet Rating) by 15.0% in the second quarter, Holdings Channel.com reports. The institutional investor owned 1,884 shares of the company’s stock after purchasing an additional 246 shares during the quarter. Cooper Financial Group’s holdings in Zoetis were worth $324,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. American National Bank raised its holdings in Zoetis by 469.2% in the 2nd quarter. American National Bank now owns 148 shares of the company’s stock valued at $25,000 after acquiring an additional 122 shares during the last quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC increased its holdings in shares of Zoetis by 430.8% in the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 138 shares of the company’s stock valued at $26,000 after purchasing an additional 112 shares during the last quarter. Worth Asset Management LLC acquired a new stake in shares of Zoetis in the first quarter valued at approximately $26,000. Financial Management Professionals Inc. lifted its position in Zoetis by 117.4% during the first quarter. Financial Management Professionals Inc. now owns 150 shares of the company’s stock worth $28,000 after buying an additional 81 shares in the last quarter. Finally, Hanson & Doremus Investment Management boosted its stake in Zoetis by 713.6% during the first quarter. Hanson & Doremus Investment Management now owns 179 shares of the company’s stock worth $34,000 after buying an additional 157 shares during the last quarter. 91.05% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Stock Down 1.2 %

Shares of ZTS opened at $157.30 on Monday. The company has a debt-to-equity ratio of 1.14, a quick ratio of 1.46 and a current ratio of 2.18. The stock has a market capitalization of $73.64 billion, a PE ratio of 35.67, a P/E/G ratio of 2.74 and a beta of 0.77. The company’s 50-day simple moving average is $169.18 and its 200-day simple moving average is $174.54. Zoetis Inc. has a 1 year low of $154.18 and a 1 year high of $249.27.

Zoetis (NYSE:ZTSGet Rating) last issued its quarterly earnings results on Thursday, August 4th. The company reported $1.20 EPS for the quarter, missing the consensus estimate of $1.22 by ($0.02). The business had revenue of $2.10 billion during the quarter, compared to analysts’ expectations of $2.03 billion. Zoetis had a net margin of 26.14% and a return on equity of 49.03%. The business’s quarterly revenue was up 7.8% on a year-over-year basis. During the same period in the prior year, the business earned $1.19 EPS. Analysts forecast that Zoetis Inc. will post 5.01 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Kristin C. Peck sold 311 shares of Zoetis stock in a transaction that occurred on Thursday, July 7th. The shares were sold at an average price of $180.00, for a total value of $55,980.00. Following the completion of the transaction, the chief executive officer now owns 39,743 shares in the company, valued at $7,153,740. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, CEO Kristin C. Peck sold 311 shares of the company’s stock in a transaction dated Thursday, July 7th. The stock was sold at an average price of $180.00, for a total transaction of $55,980.00. Following the completion of the transaction, the chief executive officer now directly owns 39,743 shares of the company’s stock, valued at approximately $7,153,740. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Kristin C. Peck sold 9,689 shares of the firm’s stock in a transaction dated Thursday, July 21st. The stock was sold at an average price of $180.00, for a total value of $1,744,020.00. Following the sale, the chief executive officer now directly owns 39,743 shares in the company, valued at approximately $7,153,740. The disclosure for this sale can be found here. Insiders have sold a total of 16,501 shares of company stock worth $2,949,073 in the last quarter. 0.12% of the stock is owned by company insiders.

Analyst Ratings Changes

Several brokerages have recently weighed in on ZTS. Stifel Nicolaus lowered their price target on shares of Zoetis from $275.00 to $225.00 and set a “buy” rating on the stock in a research report on Friday, June 24th. Piper Sandler assumed coverage on shares of Zoetis in a research note on Monday, July 11th. They issued an “overweight” rating and a $205.00 price target for the company. William Blair reaffirmed an “outperform” rating on shares of Zoetis in a research report on Friday, August 5th. StockNews.com upgraded Zoetis from a “buy” rating to a “strong-buy” rating in a research report on Friday, September 9th. Finally, The Goldman Sachs Group decreased their price target on Zoetis from $208.00 to $202.00 and set a “buy” rating on the stock in a research note on Thursday, July 21st. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $224.00.

Zoetis Company Profile

(Get Rating)

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Recommended Stories

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTSGet Rating).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.